KRAS and cancer: Farnesyltransferase inhibitors were consequently an early class of pan-RAS inhibitors which, despite many preclinical successes, failed to show success in the treatment of KRAS-mutant cancers, possibly due to alternative prenylation of KRAS (30, 31).